This study aimed to evaluate the relative association between sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1Ra) with the incidence of gout in patients with type 2 diabetes (T2D) using real-world data. We conducted a cohort study using ...
To determine whether canagliflozin mediates its action solely through OxPhos inhibition, we compared its anti-proliferative activity to that of two specific OxPhos complex-I inhibitors, BAY-87-224347and IACS-01075948. At widely used doses, these agents significantly suppressed OCR in glycolytic rate bi...
Originally designed as anti-hyperglycemic drugs, Glucagon-Like Peptide-1 receptor agonists (GLP-1Ra) and Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated protective cardiovascular effects, with significant impact on cardiovascular morbidity and mortality. Despite several mechanisms have be...
SGLT, sodium glucose co-transporterSNS, sympathetic nervous systemT2DM, type 2 diabetes mellituserythropoetininflammationketonesRecent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have dramatic beneficial cardiovascular outcomes. These include a reduced incidence of ...
SGLT2 inhibitorsBackground:Glycogen storage disease type Ib (GSD Ib) is a severe disorder of carbohydrate metabolism due to bi-allelic variants in SLC37A4. It is associated with neutropaenia and neutrophil dysfunction, which has recently been attributed to the accumulation of 1,5-anhydroglucitol-6...
SGLT2 inhibitorsOlder adults are under-represented in trials, meaning the benefits and risks of glucose-lowering agents in this age group are unclear. The aim of this study was to assess the safety and effectiveness of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in people with type 2 ...
This article, co-authored by a patient living with type 2 diabetes and a diabetes specialist physician, discusses the patient's experience of living with type 2 diabetes, including their experience of diagnosis and self-management, education and adoption of SGLT2 inhibitors to treat the disease. ...
Side effects of SGLT2 inhibitors therapy include urinary tract and genital infections. These drugs also have a diuretic effect, which can lead to the dehydration or hypotension. Some researches highlight the risks for bone fractures. SGLT2 inhibitors increase concentrations of phosphate in serum, ...
SGLT2 inhibitorssodium-glucose transporter inhibitordoi:10.1016/j.bja.2025.01.011S. PearceyWest Suffolk Hospital, Bury St. Edmunds, UKA. MorrisWest Suffolk Hospital, Bury St. Edmunds, UKR. KnaggsUniversity of Nottingham, Nottingham, UKElsevier LtdBritish Journal of Anaesthesia...
Diabetologia (2024) 67:1817–1827 https://doi.org/10.1007/s00125-024-06190-9 ARTICLE Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach Laura M. Güdemann1 · Katie G...